Review Article
Postexit Surface Engineering of Retroviral/Lentiviral Vectors
Table 1
Approaches to post-exit modification of R/LV vector surfaces.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mostly pre-exit, **not tried on R/LV, ***requires genetic modifications (transfection/transduction) to deliver part of the system. RV: retrovirus, LV: lentivirus, VSV: vesicular stomatitis virus, MV: measles virus, IV: influenza virus, HV: herpes virus, BV: baculovirus, AV: adenovirus. Lenti/retroviruses are in bold and underlined, viruses in brackets are naked viruses. P: preparation, L: labeling, H: host responses, R: range of infectivity. Objectives in brackets have not been carried out on enveloped viruses. CD59 protectin, GFP green fluorescent protein, MHC major histocompatibility complex, EGF epidermal growth factor, VEGF vascular endothelial growth factor, CEA carcinoembryonic antigen, HER human epidermal growth factor receptor 2, P-GP permeability glycoprotein, TAMRA Carboxytetramethylrhodamine. |